Physician

Ravi D Rao, MD

According to 2025 Medicare claims, Ravi Rao, MD (NPI: 1417927054) practices hematology/oncology in the Fresno, CA market, with the plurality of this provider's patient population coming from Fresno, CA. This provider's primary affiliated billing organization is CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (NPI: 1083661607; TIN: 770324589) and primary practice location at 93720-3347.

Rao's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,106 traditional Medicare patients, billed 384,987 HCPCS/CPT codes, and received $7,918,633 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 2,244 prescription claims across 347 beneficiaries totaling $7,947,762 in drug costs, led by Pomalyst (Pomalidomide). DME data shows 52 claims. Open Payments data shows 55 records totaling $14,931. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $6,370,424 to $7,918,633. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,059,226 to $7,947,762. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $19,321 to $2,316.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	702	832,944	$6,370,424
2016	774	678,824	$6,060,780
2017	793	594,967	$5,460,941
2018	871	678,100	$6,312,886
2019	934	619,498	$6,596,962
2020	1,125	629,875	$8,927,268
2021	1,159	586,049	$8,850,334
2022	1,183	639,300	$8,198,583
2023	1,342	627,243	$9,574,783
2024	1,106	384,987	$7,918,633

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	294	2,418	$2,059,226
2016	301	2,551	$3,056,249
2017	290	2,272	$2,434,648
2018	334	2,352	$3,625,074
2019	373	2,690	$4,160,066
2020	357	2,917	$5,528,664
2021	359	2,601	$6,635,772
2022	397	2,581	$7,468,363
2023	398	2,815	$7,166,013
2024	347	2,244	$7,947,762

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	14	394	$136,391
2016	24	405	$123,367
2017	N/R	350	$118,201
2018	N/R	342	$82,217
2019	26	205	$46,769
2020	N/R	115	$25,707
2021	N/R	116	$5,574
2022	N/R	126	$4,766
2023	N/R	97	$7,037
2024	N/R	52	$3,653

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	747	2,942	$10
36415	Insertion of needle into vein for collection of blood sample	758	3,912	$9
83550	Iron binding capacity	535	1,565	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	753	3,871	$8
83540	Iron level	535	1,563	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	57	1,540	$1,147,816
Cabometyx	Cabozantinib S-Malate	32	765	$901,456
Jakafi	Ruxolitinib Phosphate	32	960	$626,903
Venclexta	Venetoclax	36	1,076	$417,399
Alunbrig	Brigatinib	19	570	$376,855

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
B4152	Enteral formula, nutritionally complete, calorically dense (equal to or greater than 1.5 kcal/ml) with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit	N	N/R	13	$1,624
B4034	Enteral feeding supply kit; syringe fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape	N	N/R	13	$1,025
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	13	$811
E0431	Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing	Y	N/R	13	$194

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	50	$1,121	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	4	$13,811	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	1	$650	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Ravi D. Rao, MD?

Tedicare shows public-source Medicare data for Ravi D. Rao, MD (NPI 1417927054), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ravi D. Rao, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ravi D. Rao, MD?

Ravi D. Rao, MD is linked to CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (billing NPI 1083661607) in the available physician profile data.

Does Ravi D. Rao, MD have Open Payments data?

Ravi D. Rao, MD has 55 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.